

IN THE CLAIMS

1. (currently amended) A transdermal dosage form comprising: a non- 5α -reducible, 7α -modified androgen comprising 7α -methyl-19-nortestosterone and its pharmaceutically acceptable salts in a therapeutically effective amount, said androgen being dispersed within a pharmaceutically acceptable transdermal carrier, whereby said transdermal dosage form has a flux which is greater than that of testosterone in a similar formulation, said therapeutically effective amount comprising an amount of said non- 5α -reducible, 7α -modified androgen sufficient to deliver between about 400 to about 1,600 micrograms of said androgen in bioavailable form over a 24-hour period.

2. (canceled).

3. (original) The transdermal dosage form of claim 1 wherein said androgen is provided in an amount of between about 0.5 to about 90% by weight of the dosage form.

4. (original) The transdermal dosage form of claim 3 wherein said androgen is provided in an amount of between about 1.0 to about 80% by weight of the dosage form.

5. (original) The transdermal dosage form of claim 4 wherein said androgen is provided in an amount of between about 5.0 to about 50% by weight of the dosage form.

6. (original) The transdermal dosage form of claim 1 wherein said dosage form has a flux greater than that exhibited by an equal amount of testosterone when administered through an otherwise identical transdermal dosage form.

7. (original) The transdermal dosage form of claim 1 wherein said pharmaceutically-acceptable transdermal carrier is an ointment.

8. (original) The transdermal dosage form of claim 1 wherein said pharmaceutically-acceptable transdermal carrier is a gel.

9. (original) The transdermal dosage form of claim 1 wherein said pharmaceutically-acceptable transdermal carrier is a cream.

10. (original) The transdermal dosage form of claim 1 wherein said pharmaceutically-acceptable transdermal carrier is a lotion.

11. (original) The transdermal dosage form of claim 1 wherein said pharmaceutically-acceptable carrier is a powder.

12. (original) The transdermal dosage form of claim 1 wherein said pharmaceutically-acceptable carrier is a spray.

13. (original) The transdermal dosage form of claim 1 wherein said pharmaceutically-acceptable carrier is a transdermal patch.

14. (original) The transdermal dosage form of claim 1 wherein said transdermal carrier is selected from the group consisting of ointments, gels, creams, lotions, powders, sprays and transdermal patches.

15. (original) The transdermal dosage form of claim 1 wherein said transdermal carrier is a transdermal patch or gel.

16. (original) The transdermal dosage form of claim 1 having a flux of greater than about 4 $\mu\text{g}/\text{cm}^2/\text{hour}$.

Claims 17-22 (canceled).

23. (new) The transdermal dosage form of claim 1 wherein said pharmaceutically acceptable salt comprises the acetate.